Oncology Nurse Edition Reprints and Permissions

Article

Alisha Smallwood Licensing & Content Manager Wright's Media 2407 Timberloch Place, Suite B The Woodlands Texas 77380 Office: 281-419-5725 Toll: 877-652-5295 Fax: 281-419-5712 Email: asmallwood@wrightsmedia.comwww.wrightsmedia.com

REPRINTS

For article reprints, please contact:
Wrights Reprints
Phone: (877) 652-5295
Email: sales@wrightsreprints.com

 

PERMISSIONS

Alisha Smallwood
Licensing & Content Manager
Wright's Media
2407 Timberloch Place, Suite B
The Woodlands Texas 77380
Office: 281-419-5725
Toll: 877-652-5295
Fax: 281-419-5712
Email: asmallwood@wrightsmedia.comwww.wrightsmedia.com

 

Recent Videos
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Related Content
Teclistamab shows promising real-world effectiveness for relapsed/refractory multiple myeloma, with high response rates and manageable safety profiles.

How Has Teclistamab Administration Translated Into Community MM Settings?

ONCOLOGY Staff
December 6th 2025
Article

Teclistamab shows promising real-world effectiveness for relapsed/refractory multiple myeloma, with high response rates and manageable safety profiles.

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

How to Manage Oligometastatic Kidney Cancer? Insights From IKCS 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
December 4th 2025
Podcast

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

Over 80% of a small cohort of patients with mantle cell lymphoma achieved a complete response to ibrutinib plus venetoclax.

Ibrutinib/Venetoclax Yields Long-Term Efficacy in Japanese R/R MCL Trial

Russ Conroy
December 5th 2025
Article

Over 80% of a small cohort of patients with mantle cell lymphoma achieved a complete response to ibrutinib plus venetoclax.

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Evolutions Across NSCLC, Multiple Myeloma, and AML at Georgia Cancer Center

Girindra Raval, MD;Amany Keruakous, MD;Daniel Peters, MD
December 1st 2025
Podcast

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

The safety profile of nadunolimab in patients with triple-negative breast cancer was consistent with its known profile, and no significant signals emerged.

Nadunolimab Exhibits Comparable Efficacy Vs Chemotherapy Alone in TNBC

Roman Fabbricatore
December 5th 2025
Article

The safety profile of nadunolimab in patients with triple-negative breast cancer was consistent with its known profile, and no significant signals emerged.

Oncology care requires psychosocial support, nutrition, and survivorship, which can result in improved patient outcomes and quality of life.

Why Survivorship Matters: Creating Space in Multidisciplinary Cancer Care

ONCOLOGY Staff
December 5th 2025
Article

Oncology care requires psychosocial support, nutrition, and survivorship, which can result in improved patient outcomes and quality of life.